Relevant to holders of RHY, BDX, IIQ, UBI and maybe others, this podcast by Peter Attia with Max Diehn offers an excellent insight into cell free DNA testing (part of one of Cathie Wood's 5 platforms of innovation).
I particularly like the coverage of its advantages over protein based tests, the limitations of general screening for cancers and explaining how sensitivity and specificity is not as simple as a set of numbers for cancer.
- The motivation to develop liquid biopsies [19:15];
- History of blood-based cancer screening and understanding the predictive value of tests [25:30];
- Current state of lung cancer and the need for better screening [32:45];
- Low-dose CT scans: an important tool for managing lung cancer but with limitations [42:00];
- Using liquid biopsies to identify circulating tumor cells [47:00];
- Liquid biopsy research moves from circulating tumor cells to cell-free DNA [1:03:00];
- Zeroing-in on circulating tumor DNA in cell-free DNA [1:10:48];
- Cell-free RNA and Max’s vision for cancer detection from a blood sample [1:22:00];
- Methylation patterns and other informative signatures found in DNA [1:24:30];
- Mutation-based methods of liquid biopsies [1:26:30];
- Understanding the sensitivity and specificity of a diagnostic test [1:30:30];
- Existing clinical liquid biopsy tests and their limitations [1:37:30];
- The future of liquid biopsies [1:44:00];
- How we get to the panacea of cancer screening [1:52:00];
https://peterattiamd.com/maxdiehn/
Disc hold IIQ and UBI in SM and RL